Heart failure with reduced ejection fraction in Sweden: patient adherence and persistence to quadruple pharmacotherapy prescription - PubMed
21 hours ago
- #Real-world Evidence
- #HFrEF
- #Pharmacotherapy Adherence
- Quadruple HFrEF therapy adoption increased in Sweden from 2016 to 2023, reaching 60% of patients by 2023.
- Patient adherence to all four foundational therapies was high (>85%), with persistence rates varying from 67% to 90% across drug classes.
- Good adherence and persistence were associated with lower rates of heart failure hospitalization and cardiovascular death.
- The main limitation in achieving full quadruple therapy uptake was lower adoption of mineralocorticoid receptor antagonists (MRA) at 73% in 2023.
- The study highlights that improvements in prescribing, adherence, and persistence are feasible in real-world heart failure care.